STERIS’ (TSE:STE – Free Report) – Investment analysts at Raymond James reduced their FY2024 EPS estimates for shares of STERIS’ in a research report issued to clients and investors on Tuesday, October 15th. Raymond James analyst M. Barth now anticipates that the company will post earnings per share of $0.77 for the year, down from their previous estimate of $0.99.
STERIS’ Price Performance
STERIS’ (TSE:STE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported C$0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C$0.12 by C$0.02. The company had revenue of C$231.38 million for the quarter, compared to the consensus estimate of C$226.20 million.
STERIS’ Company Profile
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe by providing innovative healthcare and life science product and service solutions around the globe.
Featured Articles
- Five stocks we like better than STERIS’
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Survey Reveals: America’s Most Coveted Businesses in 2024
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for STERIS’ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS’ and related companies with MarketBeat.com's FREE daily email newsletter.
